Skip to main content

Development of an oral Helicobacter Pylori vaccine

Objective

Helicobacter pylori infection is highly prevalent worldwide and is an important cause of gastritis, peptic ulcer disease, and significantly gastric cancer. Because eradication requires treatment with multidrug regimens, there exists a very strong need for a vaccine to prevent initial infection.

Immunization with H pylori protein subunits in humans has shown adjuvant-related adverse effects and only moderate effectiveness. However, with much greater knowledge of the molecular basis of infection and having learnt lessons from previous vaccine developments, the current consortium have drawn together three strand that are considered critical to the development of an effective vaccine:
- Powerful, safe and multivalent antigens
- Powerful, safe and multi-acting adjuvants
- Powerful, modular and flexible oral vaccine delivery system

All three of the above innovative technologies have been proven to be effective in doing what they are required to do, namely:

- Antigens – produce antibodies against a number of key H pylori bacterial components
- Adjuvants – stimulate the immune cells to produce significant numbers of long lasting antibodies
- Delivery – formulate antigens and adjuvants together and target the stomach and intestine

This consortium (HELICOVAXOR) uniquely converges all three into a true vaccine with real potential to protect from H pylori infection. The vaccine is being designed for oral administration, efficacy, safety and temperature stability.

This consortium has assembled leading academic, industrial and regulatory groups, the activities of which will be coordinated to perform analysis of the formulations, efficacy and safety testing of the vaccines and the preparation of a regulatory dossier, all required before the product can enter human clinical studies.

If successful in pre-clinical studies, the consortium will work with vaccine companies to progress human studies and launch the product as a vaccine to confer protection from H pylori infection.

Call for proposal

FP7-SME-2012
See other projects for this call

Funding Scheme

BSG-SME - Research for SMEs

Coordinator

SUBLIMITY THERAPEUTICS LIMITED
Address
Invent Centre Dublin City University
9 Dublin
Ireland
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 1 169 500
Administrative Contact
Rosa Monica (Dr.)

Participants (10)

GOTOVAX AB
Sweden
EU contribution
€ 25 000
Address
Korvettgatan 1D
42674 Vastra Frolunda
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Jan Holmgren (Dr.)
TELORMEDIX SA
Switzerland
EU contribution
€ 108 500
Address
Via Della Posta 10
6934 Bioggio
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Alcide Barberis (Dr.)
ALLIED AUTOMATION LIMITED
Ireland
Address
Jamestown Road
11 Dublin
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Dermot O'brien (Mr.)
PARTICULAR SCIENCES LTD-PSCI
Ireland
Address
Park Avenue 26 Castleknock
15 Dublin
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Sean Quilty (Mr.)
ALMAC DIAGNOSTIC SERVICES LIMITED
United Kingdom
Address
Seagoe Industrial Estate 20
BT63 5QD Craigavon
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Gareth Maguire (Dr.)
DIAMOND BIOPHARM LIMITED
United Kingdom
Address
Gemini House, East Wing 4
CM19 5TJ Harlow
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Paul Cronin (Mr.)
THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN
Ireland
Address
College Green
2 Dublin
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Deirdre Savage (Ms.)
GOETEBORGS UNIVERSITET
Sweden
Address
Vasaparken
405 30 Goeteborg
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Ellen Rydberg (Dr.)
CORDEN PHARMA SWITZERLAND LLC
Switzerland
Address
Eichenweg 1
4410 Liestal
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Thomas Nsenda (Mr.)
MEDITOX S.R.O
Czechia
Address
Pod Zamkem 279
28125 Konarovice
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Martin Slais (Dr.)